Seite 3 von 3 ErsteErste 123
Ergebnis 21 bis 26 von 26

Thailand von Pharmakonzern auf schwarze Liste gesetzt

Erstellt von Serge, 14.03.2007, 09:18 Uhr · 25 Antworten · 2.555 Aufrufe

  1. #21
    Avatar von Serge

    Registriert seit

    Re: Thailand von Pharmakonzern auf schwarze Liste gesetzt

    Ja @Mandybaer.

    Ich habe mal bei einer sehr grossen medizinischen Konferenz fuer das Fernsehen im Hintergrund mitgearbeitet. Wenn man dann die Gespraeche im Kaemmerlein zwischen den Superstar Aerzten aus aller Welt und den Pharmakonzernen miterlebt, dann muesste Hippokrates in seinem Grab rotieren.

    Es geht in dem Geschaeft um mehr als Geld, es geht um unglaubliche Egos und wahnsinnig viel Macht. Einer der Aerzte meinte, und nicht zu unrecht, egal wer, zu uns kommen alle, und wir sagen wer lebt und wer nicht. Das ist schon fast wie Gott.

    Aber moralsich kann man es eben nicht sehen, es ist Geschaeft, fertig aus. Wer anders denkt ist naiv. Und auch ich finde das thailaendische Vorgehen in gewisser Hinsicht gut und mutig, in anderer, der Urheberrechtsverletzung, nicht, da Thailand hier sowieso schon einen schlechten Stand hat.

  3. #22
    Avatar von DisainaM

    Registriert seit

    Re: Thailand von Pharmakonzern auf schwarze Liste gesetzt

    von heute

  4. #23
    Avatar von DisainaM

    Registriert seit

    Re: Thailand von Pharmakonzern auf schwarze Liste gesetzt

    Thailand Takes on Drug Industry, and May Be Winning
    Apr 12, 11:09 AM

    By Thomas Fuller

    When Thailand announced earlier this year that it was breaking patents on drugs
    to treat HIV and heart disease, Western pharmaceutical companies reacted with
    fury. Abbott Laboratories, the maker of the AIDS drug Kaletra, took the radical
    step of withdrawing all of its new products from Thailand, depriving Thais of
    access to new drugs for rheumatoid arthritis, kidney disease, heart disease and
    high blood pressure.

    "Thailand has chosen to break patents on numerous medicines, ignoring the patent
    system," said Jennifer Smoter, a spokeswoman for Abbott, which is based near
    Chicago. "As such, we've elected not to introduce new medicines there."

    But two months after the uproar began, there are signs that Thailand has gained
    the upper hand. Its aggressive stance could be paving the way for other
    developing countries to extract lower drug prices from pharmaceutical giants in
    Europe and the United States.

    Abbott announced Tuesday that it would cut the price of Kaletra in low-and
    medium-income countries, including Thailand, to $1,000 a patient per year. That
    is less costly than any generic on the market and 55 percent less than the
    current price, the company said.

    The Swiss drug company Novartis offered an effective 75 percent price reduction
    this week in its leukemia medicine, Glivec, after Thai officials said they were
    studying a compulsory license on the drug, which would have allowed the
    government to produce it in its own factories and distribute it on a nonprofit

    Merck, the U.S. drug maker, has also offered to cut the price of its HIV drug,
    Efavirenz, here after the Thai government announced it would break the patent
    for that drug last November.

    Drug companies say they fear a spread of Thailand's confrontational strategy.

    "We don't want Thailand to be used as a springboard for other countries to do
    the same," said Teera Chakajnarodom, president of the Pharmaceutical Research
    and Manufacturers Association, an industry group in Bangkok.

    To bring drug companies to the negotiating table, Thai officials used as a
    bargaining chip a World Trade Organization rule introduced in the 1990s. The
    rule, part of the Agreement on Trade-Related Aspects of Intellectual Property
    Rights, or Trips, gives countries the right to break a patent and either produce
    the drug themselves or import generics from other countries.

    Many countries, including Brazil, Indonesia, Malaysia, Mozambique and Zambia,
    have broken or have threatened to break patents on drugs for HIV and other
    infectious diseases.

    What is new in Thailand's case is the broader categories of drugs that the
    government is aiming at.

    A groundbreaking case was the compulsory license for Plavix, a blood-thinning
    drug developed by Sanofi-Aventis of France and marketed by the U.S. company
    Bristol-Myers Squibb.

    Plavix is designed to help prevent heart attacks and strokes. The pharmaceutical
    industry says the spirit of the WTO rule is being violated: It should be used
    for national emergencies like AIDS or other fast-spreading infectious diseases,
    the industry argues.

    Thai officials make no excuses.

    "People told us, 'It's useless to negotiate with them unless you start to
    announce that you want to go for compulsory licensing," said Suwit
    Wibulpolprasert, a senior adviser on disease control at the Thai Ministry of
    Public Health. "Then they start to talk to you.' "

    "We learned that lesson," Suwit added. "After we announced our intention to
    implement compulsory licensing they knocked at our door almost every day."

    Drug companies were stunned by the quick succession of the compulsory licenses -
    and worried about the threat of more, said Paul Cawthorne, the head of Medecins
    Sans Frontieres, the medical charity, in Thailand.

    But in practice, the strategy may be nothing more than using the WTO rule as
    leverage for some old-fashioned haggling. Analysts say the government may not
    even intend to produce its own drugs. Officials note that they have not started

    "Our door is never closed," said Health Minister Mongkol na Songkhla, who is
    heading to the United States later this month to explain the government's drug
    policies. "We are willing to discuss. We are willing negotiate."

    The WTO rules are vaguely worded: Governments can act in cases of national
    emergencies. But a declaration in 2001 by WTO members also gives countries the
    "freedom to determine the grounds upon which such licenses are granted."

    In forging their more aggressive approach toward drug companies, Thai health
    officials had plenty of room to maneuver in the tumultuous political atmosphere
    that has reigned in Thailand since the military coup that ousted a civilian
    government in September.

    The current, military-appointed government has shown little reluctance to take
    bold and controversial measures, such as capital controls and crackdowns on
    foreign ownership of companies.

    After breaking the patents, Thai officials received support and plaudits from
    many global health organizations, including Medecins Sans Frontieres, the
    Clinton Foundation and Unaids, the UN agency charged with helping tackle the
    disease. People from these organizations say Thailand is taking advantage of an
    underused provision in international law that could help save lives.

    Support and sympathy for Thailand among health advocates also rose after Abbott
    announced its partial boycott in March. Medecins Sans Frontieres called the
    decision to withhold new drugs "appalling."

    Some of Abbott's investors also protested the move. Christian Brothers
    Investment Services and members of the Interfaith Center on Corporate
    Responsibility, who together own $35 million in Abbott shares, said they were
    concerned that the company's actions might damage its reputation.

    "To our knowledge, no pharmaceutical company has before withdrawn AIDS drugs in
    response to a pricing or licensing dispute," the groups said in a statement. "By
    keeping life-saving medicines like Kaletra off the shelves in Thailand, Abbott
    Labs is threatening the health of Thais who need access to these drugs for

    Abbott has reduced the price of its Kaletra capsules, an older form of the drug
    that requires refrigeration, but not its more recent tablets, which are better
    suited for Thailand's hot climate. Thai officials said Wednesday it would be
    days before the government decided whether Abbott's price reduction would
    forestall compulsory licensing.

    By breaking the patent on Kaletra, the Thai government estimates it would save
    8,000 lives, by making possible distribution to people who cannot afford it
    through the country's public health care system.

    The Pharmaceutical Research and Manufacturers Association of America argues that
    U.S. consumers are unfairly carrying the burden of financing research for the
    rest of the world.

    "Americans are effectively subsidizing other countries' health systems through
    higher prices, while having fewer medicines from which to choose," the group
    said in its complaint to the U.S. government.

    Suwit, the Health Ministry official, advises drug companies to learn from what
    he describes as a Chinese proverb: "Less profit means more profit."

    "If you sell at a lower profit per piece," he said, "people will consume more."

    (c) 2007 International Herald Tribune. Provided by ProQuest Information and
    Learning. All rights Reserved.

  5. #24
    Avatar von simon

    Registriert seit

    Re: Thailand von Pharmakonzern auf schwarze Liste gesetzt

    Sehr schwieriges Thema, grundsätzlich unterstütze ich Länder wie Brasilien und Indien die, um ihrer Bevölkerung ein gewisses Mindestmass an bezahlbaren Medikanten zu verschaffen Generika herstellen. Dass Generika für gewisse Medikamente die schon sehr lange auf dem Markt sind und die richtig grossen Cash Crops für die Pharma-multis sind, auch auf westlichen Märkten vertrieben werden finde ich auch weniger problematisch. Und sowohl Indien wie Brasilien hat ernsthafte Bemühungen unternommen um die medizinische Versorgung in ihren Ländern zu verbessern. Aber dass gerade die jetzige Übergangsregierung ihre Ausgaben für Soziales & Health Care kürzt und gleichzeitig ihre Löhne & Militärausgaben massiv erhöht finde ich eine ziemliche Schweinerei. In dem Licht betrachtet kann man sicher keineswegs von einer Notsituation sprechen, sondern vielmehr von einer simplen Reduktion der Pharmaimporte und somit einer Verbesserung der Handelsbilanz.
    Dass man auf der anderen Seite aber aggressiv mit den Pharma-Multis verhandeln muss ist auch wieder klar.. Sprich sehr gemischte Gefühle hier.


  6. #25
    Avatar von x-pat

    Registriert seit

    Re: Thailand von Pharmakonzern auf schwarze Liste gesetzt

    Ich habe gerstern eine Rede von Bill Clinton gesehen, der sich jetzt (unter anderem) um den Aufbau eines Gesundheitssystems in Rwanda beschäftigt. Clinton sagte, dass er vor einem Jahr einen Preis von $500 USD pro Patient por Jahr für Aids Medikamente mit den Pharmakonzernen ausgehandelt hatte. Der Preis wäre dieses Jahr sogar noch weiter gesunken. Wenn Thailand sich an den Verhandlungstisch setzt und eine eine garantierte Abnahmemenge und Zahlung aushandelt, warum soll das Land nicht das schaffen, was Clinton geschafft hat?

    Cheers, X-Pat

  7. #26
    Avatar von Rene

    Re: Thailand von Pharmakonzern auf schwarze Liste gesetzt

    Nicht das Medikament sondern der Preis ist ausschlaggebend

    Um der Bevölkerung lebensnotwendige Medikamente zu einem günstigeren Preis zu verkaufen, bricht Thailand den internationalen Patentschutz der Pharma-Industrie und löst damit einen gewaltigen Streit aus.
    Ein, in meinen Augen, recht guter Hintergrundbericht auf LIFE-GO


Seite 3 von 3 ErsteErste 123

Ähnliche Themen

  1. Neue schwarze Liste der EU
    Von Schwarzwasser im Forum Touristik
    Antworten: 5
    Letzter Beitrag: 01.04.10, 08:01
  2. Schwarze Liste der Fluggesellschaften
    Von Hippo im Forum Touristik
    Antworten: 4
    Letzter Beitrag: 09.04.09, 00:19
  3. schwarze liste EU
    Von rot23 im Forum Touristik
    Antworten: 3
    Letzter Beitrag: 12.09.07, 12:55
  4. Antworten: 0
    Letzter Beitrag: 24.03.07, 21:13
  5. Frankreich setzt Phuket Air auf schwarze Liste
    Von Schwarzwasser im Forum Touristik
    Antworten: 0
    Letzter Beitrag: 17.02.06, 09:40